These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9053597)

  • 21. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Second-line chemotherapy with paclitaxel for ovarian cancer].
    Lehoczky O; Bagaméri A; Udvary J; Pulay T
    Orv Hetil; 2001 Oct; 142(42):2299-301. PubMed ID: 11760646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Taxol in the treatment of ovarian neoplasm].
    Wang Y; Huang R; Huang H
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jul; 34(7):439-41. PubMed ID: 11360659
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of chemotherapy for ovarian cancer during human pregnancy: case report and literature review.
    Mantovani G; Gramignano G; Mais V; Melis GB; Parodo G; Carrucciu GM
    Eur J Obstet Gynecol Reprod Biol; 2007 Apr; 131(2):238-9. PubMed ID: 16698170
    [No Abstract]   [Full Text] [Related]  

  • 25. [Paclitaxel should be included in standard therapy of ovarian carcinoma].
    Tropé C; Kaern J; Saeter G; Gore M
    Tidsskr Nor Laegeforen; 2003 Nov; 123(21):3083-4. PubMed ID: 14618184
    [No Abstract]   [Full Text] [Related]  

  • 26. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
    Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
    Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates.
    McGuire WP
    J Clin Oncol; 2009 Oct; 27(28):4633-4. PubMed ID: 19704055
    [No Abstract]   [Full Text] [Related]  

  • 29. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Support for non-competitive trials.
    Lancet; 1999 Mar; 353(9156):855. PubMed ID: 10093971
    [No Abstract]   [Full Text] [Related]  

  • 31. Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice.
    Ahmad I; Masters GR; Schupsky JJ; Nguyen J; Ali S; Janoff AS; Mayhew E
    Oncol Res; 1999; 11(6):273-80. PubMed ID: 10691029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer.
    Earle CC; Evans WK
    Cancer Prev Control; 1997 Oct; 1(4):282-8. PubMed ID: 9765752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
    Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
    J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacotherapy in ovarian carcinoma].
    Pfisterer J; Du Bois A
    MMW Fortschr Med; 2005 Oct; 147(43):34-6. PubMed ID: 16302419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prolonged use of paclitaxel for platinum-refractory ovarian cancer--brief report].
    Tanaka H; Konishi Y; Saito H
    Gan To Kagaku Ryoho; 2001 Mar; 28(3):403-5. PubMed ID: 11265414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
    Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit.
    Ozols RF
    J Clin Oncol; 2003 Jul; 21(13):2451-3. PubMed ID: 12829660
    [No Abstract]   [Full Text] [Related]  

  • 38. [Choice of first-line chemotherapy for advanced ovarian cancer].
    Tiuliandin SA
    Vopr Onkol; 1999; 45(4):350-4. PubMed ID: 10532090
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer.
    Markman M; Lichtman SM; Homesley H; Kennedy A; Webster K; Ernst S; Omura G; Belinson J
    Gynecol Oncol; 1998 Jul; 70(1):123-6. PubMed ID: 9698488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Taxol hypersensitivity: rapid retreatment is safe and cost effective.
    Olson JK; Sood AK; Sorosky JI; Anderson B; Buller RE
    Gynecol Oncol; 1998 Jan; 68(1):25-8. PubMed ID: 9454655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.